SMS Pharmaceuticals Limited (NSE:SMSPHARMA)
India
· Delayed Price · Currency is INR 257.00
+3.10 (1.22%)
Jun 17, 2025, 3:30 PM IST
SMS Pharmaceuticals Revenue
In the fiscal year ending March 31, 2025, SMS Pharmaceuticals had annual revenue of 7.83B INR with 10.36% growth. SMS Pharmaceuticals had revenue of 2.48B in the quarter ending March 31, 2025, with 0.98% growth.
Revenue
7.83B
Revenue Growth
+10.36%
P/S Ratio
2.85
Revenue / Employee
6.54M
Employees
1,197
Market Cap
22.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 7.83B | 734.85M | 10.36% |
| Mar 31, 2024 | 7.09B | 1.87B | 35.86% |
| Mar 31, 2023 | 5.22B | 21.77M | 0.42% |
| Mar 31, 2022 | 5.20B | -433.03M | -7.69% |
| Mar 31, 2021 | 5.63B | 1.49B | 35.93% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 271.45B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |
SMS Pharmaceuticals News
- 6 weeks ago - SMS Pharmaceuticals’ Visakhapatnam facility receives WHO prequalification - Business Upturn
- 9 months ago - Stocks to Watch on Oct 3: Reliance Power, Ashoka Buildcon, CESC, SMS Pharma, PVR INOX, Zydus Lifesciences, Reliance Infra, and HealthCare Global in focus - Business Upturn
- 9 months ago - SMS Pharmaceuticals receives EDQM certification to supply Ibuprofen in Europe - Business Upturn